Article
Nuclear transcriptional condensates as drivers and therapeutic targets in NPM1-mutated AML.
Blood - 14 May 2026
Uckelmann Hannah J, Gadrey Jayant Y, Brunetti Lorenzo
Abstract excerpt
ABSTRACT: NPM 1-mutated acute myeloid leukemia (AML) is driven by aberrant HOX/MEIS1 expression, whose mechanistic basis remained unresolved for years. Recent paradigm-shifting studies show that mutant NPM1 organizes phase-separated nuclear condensates that concentrate transcriptional regulators at active chromatin, directly sustaining the pathogenic HOX/MEIS1 transcriptional program. This framework explains the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
